Manufacturer record
B.M. Pharmaceuticals: regulatory record
Last checked 3 November 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
2 batches manufactured by B.M. Pharmaceuticals (Chandigarh) were declared Not of Standard Quality between May 2022 and August 2022. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Most recent flagged batch: V2211749, Gentamicin Injection IP (GERAGEN INJECTION) (exp Apr 2024). RDTL Chandigarh (CDSCO lab) found it not of standard quality: Bacterial Endotoxins and Sterility. Listed in the August 2022 alert.
Records by type
2 records linked to B.M. Pharmaceuticals in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Gentamicin Injection IP (GERAGEN INJECTION) | Batch V2211749Mfg May 2022 · Exp Apr 2024 | Bacterial Endotoxins and SterilitySterility | RDTL ChandigarhCDSCO lab | Aug 2022 |
| Geragen ? 2 ml (Gentamicin Injection IP) | Batch V2111674Mfg Aug 2021 · Exp Jul 2023 | Description & Particulate MatterDescription | CDL KolkataCDSCO lab | May 2022 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.